The striking synergy between LAG-3 and PD-1 has been demonstrated in murine melanoma, colon cancer, and ovarian tumor models, where the dual blockade against LAG-3 and PD-1 effectively controlled tumor progression that was resistant to respective monotherapies (205, 210). The gene discussed is PDCD1; the disease is malignant colon neoplasm.